TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy

Kidney International

Volumn 71, Issue 5, 2007, Pages 431-437

  Thibaudin, D ^a,b   Thibaudin, L ^a,b   Berthoux, P ^a,b   Mariat, C ^a,b   De Filippis, J P ^a   Laurent, B ^a   Alamartine, E ^a,b   Berthoux, F ^a,b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Disease initiation, disease progression; Gene polymorphism; Idiopathic membranous nephropathy; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CAUCASIAN; CHROMOSOME 6; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; ALLELES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847233247     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002054     Document Type: Article

References (40)

1. Heymann W, Hackel DB, Harwood S et al. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Exp Biol Med 1959; 100: 660-664.
2. kerjaschki D. Pathogenic concepts of membranous glomerulopathy (MGN). J Nephrol 2000; 13(Suppl3): S96-S100.
3. Shankland SJ. New insights into pathogenesis of membranous nephropathy, editorial. Kidney Int 2000; 57: 1204-1205.
4. Montinaro V, Lopez A, Monno R et al. Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion. Kidney Int 2000; 57: 137-146.
5. Cybulsky AV, Takano T, Papillon J et al. Complement-induced phospholipase A2 activation in experimental membranous nephropathy. Kidney Int 2000; 57: 1052-1062.
6. Pippin JW, Durvasula R, Petermann A et al. DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 2003; 111: 877-885.
7. Rink L, Kircner H. Recent progress in tumor necrosis factor-alpha field. Int Arch Allergy Immunol 1996; 111: 199-209.
8. Ruddle NH. Tumor necrosis factor (TNFα) and lymphotoxin (TNFβ). Curr opin Immunol 1992; 4: 327-332.
9. Wilson AG, de Vries N, Pociot F et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA, A1, B8 and DR3 alleles. J Exp Med 1993; 177: 557-560.
10. Udalova IA, Nedospasov SA, Webb GC et al. Highly informative typing of human TNF locus using six adjacent polymorphic markers. Genomics 1993; 16: 180-186.
11. Glotz D, Bariety J, Druet PH. Glomérulonéphrites extramembraneuses. Rev Prat 1991; 41: 2424-2429.
12. Berthoux FC, Berthoux P, Hassan AA et al. Immunogéné tique des glomérulonéphrites extramembraneuses primitives. Presse Med 1990; 19: 990-993.
13. Berthoux FC, Laurent B, Le Petit JC et al. Immunogenetics and immunopathology of human primary membranous glomerulonephritis: HLA-A B DR antigens; functional activity of splenic macrophage Fcreceptors and peripheral blood T-lymphocyte subpopulations. Clin Nephrol 1984; 22: 15-20.
14. Lio D, Candore G, Colombo A. A genetically determined high setting of TNFα influences immunologic parameters of HLA-B8, DR3 positives subjects: implications for autoimmunity. Hum Immunol 2001; 62: 705-713.
15. Wu TH, Tsai CY, Yang WC. Excessive expression of the tumor necrosis factor-alpha gene in the kidneys of patients with membranous glomerulonephritis. Chug Hua I Hsueh Tsa Chih 1998; 61: 524-530.
16. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146: 1444-1455.
17. Honkanen E, von Willebrand E, Teppo AM et al. Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. Kidney Int 1998; 53: 909-917.
18. Tabibzadeh S, Kong KF, Kapur S et al. TNF-alpha induces dyscohesion of epithelial cells - association with disassembly of actin filaments. Endocr J 1995; 3: 549-556.
19. Yuan H, Takeuchi E, Taylor GA et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13: 946-956.
20. Bantis C, Heering PJ, Aker S et al. Tumor necrosis factor-a gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis. Am J Nephrol 2006; 26: 12-15.
21. Tuglular S, Berthoux P, Berthoux F. Polymorphisms of the tumour necrosis factor a gene at position -308 and TNFd microsatellite in primary IgA nephropathy. Nephrol Dial Transplant 2003; 18: 724-731.
22. Arkin CF, Wachtel MS. How many patients are necessary to assess test performance? JAMA 1990; 263: 275-278.
23. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872.
24. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399.
25. Gonzalez S, Rodrigo L, Martinez-Borra J et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003; 98: 1101-1106.
26. Turner DM, Grant SC, Lamb WR et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995; 60: 1113-1117.
27. Ponticelli C, Zucchelli P, Imbasciati E. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310: 946-950.
28. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490.
29. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy. Kidney Int 1999; 56: 666-673.
30. Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998; 31: 1-11.
31. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966.
32. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol 2003; 23: 362-372.
33. Suranyi MG, Guasch A, Hall BM et al. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis 1993; 21: 251-259.
34. Nakajima M, Kawahara S, Sakagami Y et al. Immunogold labeling of cytokines in glomeruli in children with various renal diseases. Nephron 1999; 83: 132-138.
35. Matsumoto K. Increased release of tumor necrosis factor-alpha by monocytes from patients with glomerulonephritis. Clin Nephrol 1993; 40: 148-154.
36. Bustos C, Gonzalez E, Muley R et al. Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest 1994; 24: 799-805.
37. Ihm CG, Park JK, Hong SP et al. Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nephropathy. J Korean Med Sci 1997; 12: 539-544.
38. Ducloux D, Bresson-Vautrin C, Chalopin JM. Use of pentoxifylline in membranous nephropathy. Lancet 2001; 357: 1672-1673.
39. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39(Suppl1): S46-S75.
40. Ehrenreich T, Churg J. Pathology of membranous nephropathy. Pathol Annu 1968; 3: 145-186.